More meningococcal protection for kids

The vaccine, Menactra (Sanofi Pasteur), is indicated for individuals from two years up to 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135, infectious diseases expert Professor Robert Booy said.

A vaccine protecting against meningococcal C has been funded for children at 12 months of age under the NIP since 2003.

Professor Booy, from the University of Sydney, said Menactra and another quadrivalent meningococcal vaccine, Menveo (CSL), produced similar protection.

“The two are comparable in being safe and immunogenic and both are available for teenagers and adults but Menactra is available for children down to two years of age,” he said.

Quadrivalent vaccines were pertinent for travellers to high risk areas like Asia, Africa and the Middle East, or for immunocompromised patients, he said.

Meanwhile he said there were several promising